



Dimerix

COMPANY REVIEW
DR NINA WEBSTER




Forward looking statements



This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.

Key company metrics



Dimerix board



Mark Diamond
BSc, MBA
Non-Executive Chairman

- Antisense, Faulding (Pfizer)*
- Senior pharmaceutical executive with a demonstrated record of achievement and leadership over more than 30 years within the pharmaceutical and biotechnology industries
 - Significant accomplishments in capital raising initiatives, pipeline development and licensing
 - ✓ BSc – Microbiology/immunology
 - ✓ MBA - Business



Nina Webster
PhD, MBA, M.IP.Law
CEO & Managing Director

- Acrux, Immuron, Wyeth (Pfizer)*
- Experienced in product development, commercial strategy development & execution
 - Successfully commercialised multiple pharmaceutical products globally
 - ✓ BSc (Hons) - Pharmacology
 - ✓ PhD - Pharmaceuticals
 - ✓ MBA - Business
 - ✓ M.IP.Law - Intellectual Property Law



Hugh Alsop
BSc (Hons), MBA
Non-Executive Director

- Kinosis, Hatchtech, Acrux, Mayne Pharma*
- Extensive biotech drug development & commercial manufacturing experience
 - Responsible for successful global commercialisation programs & NDA registrations
 - ✓ BSc (Hons) - Chemistry
 - ✓ MBA - Business



Sonia Poli
PhD
Non-Executive Director


- Minoryx, AC Immune, Addex, Hoffman la Roche*
- Experienced executive in pharmaceutical operations
 - Background in small molecules development and analytical development
 - ✓ BSc (Hons) - Chemistry
 - ✓ PhD – Industrial Chemistry




Clinton Snow
BEng (Hons), BCom
Non-Executive Director

- Woodside Energy, iCetana*
- ~20 years experience as a leader with a focus in management, project delivery, risk management, & assurance
 - Provides advisory services to a family office with multiple Australian biotech investments
 - ✓ BEng (Hons) - Chemical Engineering
 - ✓ BCom - Commerce

Development pipeline



Key achievements – FY23



Key elements of **ADVANZ** PHARMA partnership

ADVANZ PHARMA acquires exclusive license to commercialise DMX-200 in European Economic Area, Switzerland, UK, Australia, New Zealand and Canada

Dimerix to receive up to ~AU\$230* million in upfront and milestone payments, plus royalties

- €6.5 million in upfront payment (~AU\$10.7 million) – received November 2023
- up to €132.5 million (~AU\$219 million) in potential milestones
- Tiered royalties on net sales

Dimerix will continue to fund and execute the global ACTION3 Phase 3 study for DMX-200 in FSGS patients


Advanz will be responsible for submission and maintenance of the regulatory dossier in the licensed territories, as well as all sales and marketing activities

Dimerix retains all rights to DMX-200 in all other territories


Global partnering availability

■ Licensed territories (EAA, Switzerland, UK, Canada, Australia/New Zealand) – DMX-200

■ Available for licensing -  **QYTOVRA**[®]
[REPAGERMANIUM]



FSGS market size


 FSGS in 7MM market size estimated to be **US\$3b** p.a¹

 Assuming US\$9,900k/month as example pricing in the US (same pricing as sparsentan in IgAN)²

 Current market specifically for FSGS does not exist

FSGS Market Size		
Region	Estimated diagnosed patients (2022)	\$US p.a (2032)
US	85,342 ¹	US\$2.05 billion ¹
EU/UK	85,014 ¹	US\$990 million ¹
Japan	32,644 ¹	US\$225 million ¹
China	>100,000 ⁴	US\$2.8 billion ³

Licensed

7 major markets (MM)

Market size of other regions including LATAM and MENA also available

The logo for ACTION3 FSGS CLINICAL STUDY. The word "ACTION3" is in large, bold, black letters. The letter "O" is replaced by a green gear with a white brain icon inside it. Above the "O" are two smaller gears, one green and one grey. Below "ACTION3" is the text "FSGS CLINICAL STUDY" in a smaller, green, sans-serif font.

ACTION3
FSGS CLINICAL STUDY

Phase 3 Update




What is Focal Segmental Glomerulosclerosis (FSGS)?

Normal glomerulus²



FSGS glomerulus²




Segmental sclerosis

Glomeruli are the tiny network of blood vessels that are the “cleaning units” of the kidney

- FSGS makes up approximately 10% of all kidney diseases¹
- On average FSGS progresses to kidney failure within 5 years after onset of proteinuria¹
- Currently no approved drugs for FSGS
 - patients are treated with medications off-label, including angiotensin receptor blockers
- Significant burden on global health systems to support healthcare economics / drug pricing
 - Patients end up on dialysis (est cost US\$90,000/patient/year)⁴
 - Patients requiring kidney transplant (est cost US\$442,500 per transplant + ongoing medication fees)⁵
 - 60% patients have reoccurring FSGS even after first kidney transplant⁶

Competitive landscape in FSGS

DMX-200 is the only therapy in phase 3 development



DMX-200 phase 2 data is clinically meaningful

NKF-FDA-EMA workshop¹ :


"eGFR slope reduction of 0.5–1.0 ml/min/1.73 m²/year may be associated with lower end stage kidney disease risk"

Kidney survival study (2020)²:

"reductions ~10% in proteinuria translated to clinically meaningful differences in eGFR slope 0.5 - 1 mL/min/ 1.73 m² per year"

Dimerix Phase 2 study:

observed a 17% reduction in proteinuria versus placebo




Phase 2 DMX-200 treatment resulted in clinically meaningful improvements in kidney function of FSGS patients



FSGS CLINICAL STUDY

Phase 3 clinical trial

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB




See: <https://dimerix.com/wp-content/uploads/2022/12/FINAL-ACTION3-pivotal-Phase-3-study-assessing-the-CCR2-inhibitor-DMX-200-in-patients-with-focal-segmental-glomerulosclerosis.pdf>

Part 1 analysis set for March 2024

- Announcement of Part 1 analysis of Phase 3 trial expected on, or around, 15 March 2024*
- A successful outcome would represent a clinically and statistical meaningful improvement in proteinuria vs placebo and the trial is continuing to Part 2



Investment highlights





A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases.

WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN

ESG Statement

Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.



SCAN ME

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. investor@dimerix.com